Enhanced NObioavailabilityindicatesimproved______.Whichnormotensivestrain served asour control?_____________In our study,follistatin wasadministered toSHRs over aperiod of______ weeks.What assay didwe use toquantifyhydrogenperoxide?_____________What is theendogenousprotein we studiedthat antagonizesactivin?_____________FST wasadministeredevery______ day.Follistatinretains itsantioxidanteffect evenwhen denatured.True/FalseWhat does theabbreviation'SHR' stand for? _____________Whichhypertensiveanimal modeldid we use?___________Follistatintreatmentreduced bloodpressure byapproximately______ mmHg.Follistatintreatment induces______ of PVAT, aphenotypeassociated withimproved vascularfunction.Which proteinmarker indicatesa brown adiposephenotype inPVAT?_____________Follistatinmust maintainits proper______ to befunctional.Follistatinincreases theexpression of______, which iscritical for nitricoxide production.The fluorescentproductproduced in theAmplexRedassay is called______.FST’santioxidanteffect is lostif it is______.Hypertension isdefined bysustained bloodpressure above____ mmHg.Follistatin isknown toneutralizesignaling by______.Our assaydirectlymeasureshydrogen______ levels.Neutralizingantibodiestargetedactivin A and______.Which type of assayis used to evaluateNO levels in ourstudy: fluorometricor colorimetric? _____________"In our experiments,the reduction inoxidative stress wasmeasured as adecrease in the foldchange of ______.Our study showsthat blockingactivin signalingreduces ______production.FST lowersROS levels, asindicated by adecrease in______ levels.Enhanced NObioavailabilityindicatesimproved______.Whichnormotensivestrain served asour control?_____________In our study,follistatin wasadministered toSHRs over aperiod of______ weeks.What assay didwe use toquantifyhydrogenperoxide?_____________What is theendogenousprotein we studiedthat antagonizesactivin?_____________FST wasadministeredevery______ day.Follistatinretains itsantioxidanteffect evenwhen denatured.True/FalseWhat does theabbreviation'SHR' stand for? _____________Whichhypertensiveanimal modeldid we use?___________Follistatintreatmentreduced bloodpressure byapproximately______ mmHg.Follistatintreatment induces______ of PVAT, aphenotypeassociated withimproved vascularfunction.Which proteinmarker indicatesa brown adiposephenotype inPVAT?_____________Follistatinmust maintainits proper______ to befunctional.Follistatinincreases theexpression of______, which iscritical for nitricoxide production.The fluorescentproductproduced in theAmplexRedassay is called______.FST’santioxidanteffect is lostif it is______.Hypertension isdefined bysustained bloodpressure above____ mmHg.Follistatin isknown toneutralizesignaling by______.Our assaydirectlymeasureshydrogen______ levels.Neutralizingantibodiestargetedactivin A and______.Which type of assayis used to evaluateNO levels in ourstudy: fluorometricor colorimetric? _____________"In our experiments,the reduction inoxidative stress wasmeasured as adecrease in the foldchange of ______.Our study showsthat blockingactivin signalingreduces ______production.FST lowersROS levels, asindicated by adecrease in______ levels.

Follistatin to the Rescue: Bingo for Lowering Pressure and Defeating ROS - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Enhanced NO bioavailability indicates improved ______.
  2. Which normotensive strain served as our control? _____________
  3. In our study, follistatin was administered to SHRs over a period of ______ weeks.
  4. What assay did we use to quantify hydrogen peroxide? _____________
  5. What is the endogenous protein we studied that antagonizes activin? _____________
  6. FST was administered every ______ day.
  7. Follistatin retains its antioxidant effect even when denatured. True/False
  8. What does the abbreviation 'SHR' stand for? _____________
  9. Which hypertensive animal model did we use? ___________
  10. Follistatin treatment reduced blood pressure by approximately ______ mmHg.
  11. Follistatin treatment induces ______ of PVAT, a phenotype associated with improved vascular function.
  12. Which protein marker indicates a brown adipose phenotype in PVAT? _____________
  13. Follistatin must maintain its proper ______ to be functional.
  14. Follistatin increases the expression of ______, which is critical for nitric oxide production.
  15. The fluorescent product produced in the AmplexRed assay is called ______.
  16. FST’s antioxidant effect is lost if it is ______.
  17. Hypertension is defined by sustained blood pressure above ____ mmHg.
  18. Follistatin is known to neutralize signaling by ______.
  19. Our assay directly measures hydrogen ______ levels.
  20. Neutralizing antibodies targeted activin A and ______.
  21. Which type of assay is used to evaluate NO levels in our study: fluorometric or colorimetric? _____________
  22. "In our experiments, the reduction in oxidative stress was measured as a decrease in the fold change of ______.
  23. Our study shows that blocking activin signaling reduces ______ production.
  24. FST lowers ROS levels, as indicated by a decrease in ______ levels.